Pfizer’s record year – topped the $100 billion mark

In 2022 Pfizer, as the first pharmaceutical company in history, reached an annual revenue of more than 100 billion dollars, thereby surpassing Johnson & Johnson as the industry’s top selling business.

By Anders Göransson

April 21, 2023 2:27 PM

It was primarily a huge boost from sales of products linked to the covid-19 pandemic – mainly the vaccine Comirnaty and the antiviral drug Paxlovid – that resulted in the company’s historically high revenue, reports Fierce Pharma, which has published a top 20 list of pharma companies by revenue (see below).

Johnson & Johnson had to settle for second place, followed by Roche, MSD and Abbvie, with Swedish-British Astra Zeneca coming in at ninth place.

The top 20 pharma companies by 2022 revenue (2021 revenue)

1. Pfizer $100,33 billion (81,29)

2. Johnson & Johnson $94,94 billion (93,77)

3. Roche $66,26 billion (68,71)

4. MSD (Merck & Co) $59,28 billion (48,70)

5. Abbvie $58,05 billion (56,20)

6. Novartis $50,54 billion (51,63)

7. Bristol Myers Squibb $46,16 billion (46,38)

8. Sanofi $45,22 billion (44,63)

9. AstraZeneca $44,35 billion (37,42)

10. GSK $36,15 billion (46,92)

11. Takeda Pharmaceutical Company $30,00 billion (31,57)

12. Eli Lilly $28,55 billion (28,32)

13. Gilead Sciences $27,28 billion (27,30)

14. Bayer $26,64 billion (27,94)

15. Amgen $26,32 billion (25,98)

16. Boehringer Ingelheim $25.28 billion (24,24)

17. Novo Nordisk $25,00 billion (22,38)

18. Moderna $19,26 billion (18,47)

19. Merck KGaA $19,16 billion (19,11)

20. Biontech 18,20 billion (22,43)

Source: Fierce Pharma

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.